

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(19)



Europäisches Patentamt  
European Patent Office  
Offic européen des brevets



(11) Publication number:

**0 428 541 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**(45) Date of publication of patent specification: **30.08.95** (51) Int. Cl.<sup>6</sup>: **A61K 38/39**(21) Application number: **89908119.4**(22) Date of filing: **28.06.89**(86) International application number:  
**PCT/US89/02799**(87) International publication number:  
**WO 90/00060 (11.01.90 90/02)**

The file contains technical information submitted  
after the application was filed and not included in  
this specification

(54) **COLLAGEN WOUND HEALING MATRICES AND PROCESS FOR THEIR PRODUCTION.**(30) Priority: **30.06.88 US 213726**  
**16.12.88 US 286303**(43) Date of publication of application:  
**29.05.91 Bulletin 91/22**(45) Publication of the grant of the patent:  
**30.08.95 Bulletin 95/35**(84) Designated Contracting States:  
**AT BE CH DE FR GB IT LI LU NL SE**

(56) References cited:

|                        |                        |
|------------------------|------------------------|
| <b>EP-A- 0 042 253</b> | <b>EP-A- 0 154 447</b> |
| <b>EP-A- 0 171 176</b> | <b>EP-A- 0 243 179</b> |
| <b>US-A- 4 553 974</b> | <b>US-A- 4 725 671</b> |
| <b>US-A- 4 789 663</b> | <b>US-A- 4 795 467</b> |

(73) Proprietor: **COLLAGEN CORPORATION**  
**2500 Faber Place**  
**Palo Alto, California 94303-3334 (US)**

(72) Inventor: **CHU, George, H.**  
**510 Kinross Court**  
**Sunnyvale, CA 94087 (US)**  
Inventor: **OGAWA, Yasushi**  
**310 Farallon Avenue**  
**Pacifica, CA 94044 (US)**  
Inventor: **McPHERSON, John, M.**  
**31 Valleywood Road**  
**Hopkinton, MA 01748 (US)**  
Inventor: **KSANDER, George**  
**437 Northumberland Avenue**  
**Redwood City, CA 94061 (US)**  
Inventor: **PRATT, Bruce**  
**5 Blueberry Hill Road**  
**Med Way, MA 02053 (US)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**EP 0 428 541 B1**

**COLLAGEN AND RELATED RESEARCH CLINICAL AND EXPERIMENTAL**, vol. 8, no. 1, January 1988, pages 83-100, Gustav Fischer, Stuttgart, DE; J.M. McPHERSON et al.: "The influence of heparin on the wound healing response to collagen implants invivo"

**JOURNAL OF BIOMEDICAL MATERIALS RESEARCH**, vol. 20, no. 8, October 1986, pages 1219-1228, John Wiley & Sons; C.J. DOILLON et al.: "Collagen-based wound dressings: Control of the porestructure and morphology"

WO 85/04413

Inventor: HENDRICKS, Diana  
390 W. Glen Oaks  
Brea, CA 92621 (US)  
Inventor: McMULLIN, Hugh  
3133 Shelter Creek Lane  
San Bruno, CA 94066 (US)

⑦ Representative: Goldin, Douglas Michael et al  
J.A. KEMP & CO.  
14, South Square  
Gray's Inn  
London WC1R 5LX (GB)

**Description**Technical Field

5 This invention is in the field of collagen chemistry and wound implants. More specifically, it relates to solid matrices of collagen that are useful as wound healing implants and sustained-release depots for administering bioactive agents, and processes for their preparation.

Background

10 Wound healing implants should have the ability to adhere and conform to the wound site, and ideally should facilitate regrowth of epidermis, and accumulation of fibroblasts, endothelial cells, and wound healing regulatory cells into the wound site to speed healing (e.g., promotion of connective tissue deposition and angiogenesis). Whether a given implant can meet these objectives is a reflection of the chemical  
15 composition and physical characteristics of the implant.

Collagen, the major protein of connective tissue, has been used previously in wound dressings. Procedures for rendering xenogeneic collagen substantially nonimmunogenic are available. U.S. 4,412,947 describes an absorbent dressing having a bulk density of 0.005 to 0.0065 g/cm<sup>3</sup> made by freeze drying a dispersion of native collagen in a weak aqueous organic acid solution. Such dressings that are made from  
20 acid solution have tightly woven fibers with typically low absorptive capacity and pore sizes that do not encourage optimum cell ingrowth.

PCT Application No. 85/04413 describes a carbodiimide or succinimidyl ester cross-linked collagen sponge formed from a dispersion or solution of collagen that is dehydrated before or after the collagen is cross-linked by addition of the cross-linking agents. Collagen sponges made in this manner have similar  
25 disadvantages to those made from the freeze dried acid solution.

Other references describing collagen sponges are U.S. Patents Nos. 3,742,955, 3,743,295, 3,810,473, 4,515,637, and 4,578,067. EP-A-0 171 176 describes collagen implants for bone repair. The implants are made using a suspension of collagen of a concentration of approximately 20-100 mg/ml which are cast into  
30 molds or extruded into sheets.

The present invention is directed to providing collagen implants that are biocompatible, biodegradable, and are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. Another aspect of the invention is directed to providing a collagen matrix useful for sustained delivery of  
35 bioactive agents.

Disclosure of the Invention

The present invention encompasses novel collagen implants that are useful as wound healing matrices, and processes for making those implants.

40 These collagen implants are characterized in that the collagen is biocompatible, biodegradable, substantially nonpyrogenic, fibrillar, and not chemically cross-linked; and the implant has a bulk density of 0.01 to 0.3 g/cm<sup>3</sup>, and a pore population in which at least about 80% of the pores are of a size sufficient to permit cell ingrowth. Thus the present invention provides a collagen implant, comprising, a matrix having a density of about 0.01 to about 0.3 g/cm<sup>3</sup>, a thickness of about 1-20 mm, and having pores at least 80% of  
45 which are at least 35  $\mu$ m in diameter, wherein said matrix comprises fibrillar atelopeptide collagen, wherein said fibrils are about 50-200 nm in diameter, and are not chemically cross-linked.

The wound healing implant also serves as an effective sustained delivery vehicle for bioactive additives, such as heparin or other glycosaminoglycans, extracellular matrix proteins, antibiotics, and growth factors, for example, epidermal growth factor (EGF), platelet derived growth factor (PDGF), fibroblast growth factor (FGF), connective tissue activating peptides (CTAP), transforming growth factors (TGFs) and the like. A  
50 presently preferred embodiment for wound healing comprises acidic fibroblast growth factor (aFGF) and transforming growth factor beta (TGF- $\beta$ ) in synergistic amounts. By virtue of effectively delivering such bioactive factors, the implants of the invention are also useful in oncostasis, immunomodulation, osteogenesis, and hematopoiesis. Nonbioactive agents such as preservatives, antimicrobials, or dyes may also be incorporated into the implant.

55 The process for making the implants comprises the steps of:  
(a) providing an acidic aqueous solution of atelopeptide collagen at a concentration of collagen of from 2 to less than 20 mg/ml;

- (b) precipitating the collagen from the solution by raising the pH of the solution, forming a homogenous dispersion of the precipitated collagen fibrils;
- (c) casting the dispersion to a desired thickness;
- (d) flash-freezing the cast dispersion at a temperature below about -20 ° C; and
- (e) lyophilizing the frozen cast dispersion to form a substantially moisture-free collagen matrix.

Optionally, bioactive additives can be added to the homogeneous dispersion at step (b) above, or immediately following step (b). Alternatively, one may soak the dried implant in a solution containing the bioactive agent, or by using a sterile pipet or dropper and dropping a solution containing the bioactive agent onto the dried implant.

Additional aspects of the invention include further steps in the above process such as compressing the implant to form implants having bulk densities in the upper portion of the above mentioned range and/or heat treating (curing) the implant to increase its tensile strength.

#### Brief Description of the Drawings

Figure 1 is a scanning electron microscope photograph of a collagen implant of this invention illustrating its characteristic structure.

Figure 2 is a transmission electron microscope photograph of a collagen implant of the invention illustrating the fibrillar structure.

Figure 3 depicts the results disclosed in Example 9.

#### Modes for Carrying Out the Invention

##### A. Preparation of Collagen Implants

The present invention preferably employs collagen in solution (CIS) as a starting material. An acidic solution of an atelopeptide form of bovine skin collagen is commercially available from Collagen Corporation, Palo Alto, California, under the trademark Vitrogen® 100. This material is a solution containing about 3 mg/mL of collagen at a pH of approximately 2.0. As indicated below, it is preferable to concentrate the Vitrogen® 100 solution for use in the invention. Any solubilized form of collagen can, of course, be employed as a starting material, including bovine tendon collagen, human collagen, and the like.

The collagen used is not chemically cross-linked, e.g., by the addition of aldehydes or other chemical additives which react with the collagen to form covalent bonds. If desired, the collagen matrix may be heat-treated as described below: this may effect a form of covalent bonding, but does not require the addition of chemical cross-linking agents. Chemical cross-linking agents excluded from the invention are also distinguished from biological molecules which may have a non-covalent affinity for collagen, such as glycosaminoglycans, e.g., heparin. Such molecules which do not bind covalently in solution are within the scope of this invention.

The concentration of collagen in the starting solution can vary from about 2 to less than 20 mg/ml. The concentration plays a part in the properties of the collagen implant product. Concentrations in the lower part of this range give products having relatively low tear strengths that degrade more rapidly in aqueous environments. Higher concentrations in the range give denser, stronger implants which degrade slowly in aqueous environments. Preferred concentrations are in the range of about 4 to less than 20 mg/ml.

The concentration of collagen can be adjusted downwards, if necessary, by simple dilution. Upwards adjustments can be made using methods which do not damage the collagen such as by precipitating the collagen and redissolving it at the higher concentration.

In the process the collagen in solution is precipitated by raising the pH of the solution to approximately neutral pH or higher, such as by adding an alkaline buffer or the like to form a homogeneous dispersion of reconstituted fibrillar collagen. Typical buffers include inorganic (e.g. phosphate) and organic (e.g., acetate) buffers.

The homogeneous dispersion that results is cast into a sheet. With low collagen concentration dispersions, this can be done by merely pouring the dispersion into the casting zone. With more concentrated materials it may be helpful or necessary to spread the material with a blade or similar instrument to provide a uniform layer. The thickness of the cast layer of dispersion is generally from about 1 to about 20 mm thick, with thicknesses of from about 2 to about 8 mm being preferred.

The cast layer is then frozen under rapid or "flash freezing" chill conditions. If the freezing is slow and gradual, the size of the ice crystals formed in the layer will be large and the resulting final product will have inconsistent pore sizes. One typical flash-freezing method involves casting on a high heat conductivity

surface, such as a metal surface, and then placing this high heat conductivity surface in intimate contact with a volume of chilled liquid or another chilled metal surface such that the heat is rapidly drawn from the cast layer. The temperature employed for this chilling is generally less than  $-40^{\circ}\text{C}$ , and preferably is less than  $-50^{\circ}\text{C}$  and more preferably is in the range of from  $-65^{\circ}\text{C}$  to about  $-110^{\circ}\text{C}$ .

5 The frozen layer is then lyophilized by methods known in the art. The lyophilization temperature is preferably as high as possible without permitting melting of the layer. In view of the dissolved collagen and accompanying salts and buffers in the fluid,  $-5^{\circ}\text{C}$  is generally the highest nonmelting temperature, with temperatures of from about  $-25^{\circ}\text{C}$  to about  $-10^{\circ}\text{C}$  being preferred. Generally, temperatures below about  $-30^{\circ}\text{C}$  give very slow rates of lyophilization. The vacuum employed for lyophilization can vary. Ultrahigh  
10 vacuums are not required, however, with absolute pressures in the range of from about 0.0133 mbar (0.01 torr) to about 0.1333 mbar (0.1 torr) generally being employed. The time required to lyophilize the layer will depend upon the layer's thickness, but generally, times in the range of from about 4 hours to about 30 hours are employed. The actual times employed will depend upon the temperature and vacuum employed. After lyophilization, the layer will typically be substantially free of water (i.e., it contains less than about 25%  
15 by weight moisture, preferably less than about 10% by weight moisture). If necessary, the implant may be dried after the lyophilization to remove all water.

Additional optional steps may be added to the process to alter the properties of the resulting collagen implant. In one option, the process includes an additional step in which an inert gas is admixed with the collagen dispersion prior to casting. In this additional step an inert gas is suspended in the viscous collagen  
20 dispersion to produce a gas-in-semisolid dispersion. The type of inert gas used is not critical. Air is the usual gas of choice, but argon, nitrogen or any other gas which will not react with the collagen and which will not leave pharmacologically unacceptable residues in the final product can be used. The volume of gas incorporated into the collagen dispersion will range from about 0.33 to about 3 volumes per volume of dispersion. Preferably, the volume of gas is from about 0.5 to about 2 volumes per volume of dispersion.

25 The method of incorporating the gas into the dispersion must be a low shear method. A high speed blender or mixer is unacceptable as it will lead to physical degradation of the structure of the collagen. Suitable mixing methods include bubbling, sparging, or pumping the gas into the dispersion, shaking the two phases together, gently mixing the two phases with a paddle mixer, and the like. The gas-in-semisolid dispersion that results from the above-noted incorporation is then cast and processed as set forth above.

30 In another option, the implant is compressed to increase its bulk density. Compressed implants typically have bulk densities in the range of 0.05 to 0.3  $\text{g}/\text{cm}^3$ , whereas noncompressed implants normally have bulk densities of 0.01 to 0.05  $\text{g}/\text{cm}^3$ . Compression can be accomplished by passing a sheet of the product through a press, or through rollers or the like to achieve the desired degree of compression. Compression will also decrease the thickness of the implant.

35 In another variation of the above process, multilayer products can be formed by serially casting and flash freezing a plurality of layers and thereafter lyophilizing and drying. This variation can be useful to deposit a layer or "skin" of collagen on one or both sides of the implant without having to laminate the layers together. Such a skin is usually less than about a millimeter thick, such as from 0.1 mm to about 0.75 mm. In a typical embodiment, a 1 mm thick layer of a collagen dispersion having the characteristics of the  
40 dispersion used in the main process before gas addition is cast and flash frozen. Thereafter, the dispersion of fibrillar collagen with or without suspended gas is cast and flash frozen. This multilayer composite is then lyophilized.

When producing a multilayer material, it is generally preferred to cast and freeze the individual layers and then lyophilize the entire composite at once. The same conditions described for freezing the individual  
45 layers may be for multi-layer composites. Lyophilizing times and conditions generally are cumulated when applied to a composite material. Implants may be laminated with other biocompatible materials if desired.

In another variation of the process the dry (less than 10% by weight moisture) collagen implant is heat cured to increase its strength without affecting pore size or absorbency adversely. The curing will normally take place at atmospheric pressure or under vacuum at temperatures in the range of  $60^{\circ}\text{C}$  to  $120^{\circ}\text{C}$ ,  
50 preferably  $75^{\circ}\text{C}$  to  $90^{\circ}\text{C}$ . Relative humidity during the curing step is kept below about 55%. The curing will normally take between 4 h and one week and may be carried out in open or closed containers. The strength time (as defined in Example 4, *infra*) of the cured implants will normally be greater than about 20 s, more normally greater than about 50 s, depending on the thickness of the implant.

In still another option, glycosaminoglycans, bioactive agents, and/or non-bioactive agents are added to  
55 the collagen dispersion prior to flash-freezing and lyophilization. Alternatively, one may soak the dried implant in a solution containing the preferred additive, or by using a sterile pipet or dropper and dropping a solution containing the additive onto the dried implant.

The addition of bioactive agents or protein factors enhances the ability of the wound healing matrices to promote wound healing. One or more bioactive agents may be incorporated to promote granulation tissue deposition, angiogenesis, reepithelialization, and fibroplasia. Additionally, these and other factors are known to be effective immunomodulators (either locally or systemically), hematopoietic modulators, osteoinductive agents, and oncostatic agents (e.g., TGF-beta has been shown to exhibit all of these activities). The bioactive additives or protein factors used herein may be native or synthetic (recombinant), and may be of human or other mammalian type. Human FGF (including both acidic or basic forms), PDGF, and TGF-beta are preferred. The incorporation of approximately equal amounts of FGF and TGF-B significantly enhances granulation tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The bioactive additives or protein factors used herein may be native or synthetic (recombinant), and may be of human or other mammalian type. Methods for isolating aFGF from native sources (e.g., pituitary, brain tissue) are described in K.A. Thomas et al, *Proc Nat Acad Sci USA* (1984) 81:357-61. Methods for isolating PDGF from platelets are described by Rainer et al, *J Biol Chem* (1982) 257:5154. Kelly et al, *EMBO J* (1985) 4:3399 discloses procedures for making recombinant forms of PDGF. Methods for isolating TGF-beta1 from human sources (platelets and placenta) are described by Frolik et al in EP-A-128,849 (19 December 1984). Methods for isolating TGF-beta1 and TGF-beta2 from bovine sources are described by Seyedin et al, EP-A-169,016 (22 January 1986), and U.S. Pat. No. 4,774,322. Other factors within the scope of this invention include, without limitation, transforming growth factor-alpha, beta-thromboglobulin, insulin-like growth factors (IGFs), tumor necrosis factors (TNFs), interleukins (e.g., IL-1, IL-2, etc.), colony stimulating factors (e.g., G-CSF, GM-CSF, erythropoietin, etc.), nerve growth factor (NGF), and interferons (eg., IFN-alpha, IFN-beta, IFN-gamma, etc.). Synthetic analogs of the factors, including small molecular weight domains, may be used provided they exhibit substantially the same type of activity as the native molecule. Such analogs are intended to be within the scope of the term "bioactive agent," "bioactive substance," and "bioactive additive," as well as within the specific terms used to denote particular factors, e.g., "FGF," "PDGF," and "TGF-beta." Such analogs may be made by conventional genetic engineering techniques, such as via expression of synthetic genes or by expression of genes altered by site-specific mutagenesis. In some cases, such as with PDGF, the factor may be incorporated into the composition in its native form (i.e., in platelets), or as crude or partially purified releasates or extracts. Alternatively, the factors may be incorporated in a substantially pure form free of significant amounts of other contaminating materials.

The term "TGF-B" as used herein refers to transforming growth factor-beta, including TGF-B1, TGF-B2, other protein factors having TGF-B activity and at least 70% homology, and mixtures thereof. TGF-B may be derived from natural sources, or may be prepared by recombinant methods. One may also prepare muteins of TGF-B, wherein one or more amino acids are substituted or deleted, as long as substantial TGF-B activity is retained. TGF-B2 is presently preferred.

The term "FGF" refers to both acidic and basic fibroblast growth factor. Acidic FGF (aFGF) is also known in the art as endothelial cell growth factor, eye-derived growth factor II, heparin-binding growth factor alpha, retinal-derived growth factor, astroglial growth factor 1, and prostatropin. Basic FGF (bFGF) is also known as eye-derived growth factor I, heparin-binding growth factor beta, astroglial growth factor 2, cartilage-derived growth factor, and chondrosarcoma-derived growth factor. As used herein, "aFGF" includes aFGF derived from any suitable species, or produced through recombinant methods. One may also prepare muteins of aFGF, wherein one or more amino acids are substituted or deleted, as long as substantial aFGF activity is retained. Recombinant human aFGF is presently preferred. Proteins similarly related to bFGF are also included, as are mixtures of bFGF and aFGF or derivatives thereof.

An "immunomodulatory amount" of factor is an amount of a particular factor sufficient to show a demonstrable effect on the subject's immune system. Typically, immunomodulation is employed to suppress the immune system, e.g., following an organ transplant, or for treatment of autoimmune disease (e.g., lupus, auto-immune arthritis, autoimmune diabetes, etc.). For example, when transplanting an organ one could line the site with the matrix of the invention impregnated with an immunomodulatory amount of an immunosuppressive biological growth factor to help suppress rejection of the transplanted organ by the immune system. Alternatively, immunomodulation may enhance the immune system, for example, in the treatment of cancer or serious infection (e.g., by administration of TNF, IFNs, etc.).

An "oncostatically effective amount" is that amount of growth factor which is capable of inhibiting tumor cell growth in a subject having tumor cells sensitive to the selected factor. For example, many non-myeloid carcinomas are sensitive to treatment with TGF-beta, particularly TGF-beta2, as set forth in U.S. Pat. No. 4,816,442.

A "hematopoietically modulatory amount" is that amount of growth factor which enhances or inhibits the production and/or maturation of blood cells. For example, erythropoietin is known to exhibit an enhancing activity at known dosages, while TGF-beta exhibits an inhibitory effect.

An "osteoinductive amount" of a biological growth factor is that amount which causes or contributes to a measurable increase in bone growth, or rate of bone growth.

The amount of the factor included in the composition will depend upon the particular factor involved, its specific activity, the type of condition to be treated, the age and condition of the subject, and the severity of the condition. For example, it may be necessary to administer a higher dosage of TGF-beta when treating, for example, adenocarcinoma (e.g., by applying a TGF-beta-containing matrix to the wound after surgical excision of a tumor, before closing) than when simply promoting the healing of a wound (e.g., due to trauma or surgical procedure). In most instances, the factors will each be present in amounts in the range of about 0.07 to about 200  $\mu\text{g}/\text{cm}^2$  based on surface area to be treated. A more preferred range is about 0.5 to 30  $\mu\text{g}/\text{cm}^2$ , especially about 3.0 to about 18  $\mu\text{g}/\text{cm}^2$ .

The addition of heparin to the dispersion has been found to affect the pore size of the implant. When heparin is added the heparin concentration in the dispersion before flash-freezing will normally be between 5 and 300  $\mu\text{g}/\text{mL}$ . An "effective amount of heparin" is that amount which provides the desired pore size in the final product matrix.

## B. Characteristics of Collagen Implants

The collagen implants of this invention are coherent nonwoven bodies of collagen fibrils that are characterized by a very consistent, finely fibered structure. Figure 2 is a transmission electron micrograph of a typical fibrillar product illustrating its fibrillar structure. This structure is further characterized by being made up of fibrils which are essentially uniform diameter circular cross section fibers. The average diameter of these fibrils is normally from about 50 to about 200 nm, more usually from about 100 nm to about 150 nm. Another characteristic of the implants is that they have a bulk density in the range of 0.01 to 0.3  $\text{g}/\text{cm}^3$ .

Yet another characteristic of the implants is that about 80% of the pores of the implant are of a sufficient size to permit cell ingrowth. In this regard at least about 80% of the pore population will have pores of at least 35 micrometers or greater in diameter, preferably 50 to 250 microns in diameter.

Approximately 1-2% of the heat-treated implant is soluble in acid solution, whereas more than 25% of the non-heat treated implant is soluble.

The fibrous implants will usually be about 2 to about 8 mm thick and are useful as wound healing matrices, surgical dressings, burn dressings and the like. The implants of the invention provide a matrix having the necessary characteristics to permit and encourage healing or promotion of connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia of tissue, even in the absence of additional growth factors. The amount of implant used in wound treatment is typically selected to substantially cover the wound, at a thickness determined by the thickness of the implant material (typically 1-8 mm). The implant may easily be cut to shape in order to fill the wound closely. Where a void is created, e.g., by excision of a tumor or cyst, the implant material may be moistened and packed into the space created.

As indicated previously, the implants are biodegradable and serve as sustained delivery vehicles for pharmaceutically active (bioactive) substances or other excipients into the implants. These additives may be added to the implant after it is formed, e.g., after lyophilization, or may be incorporated in the casting fluid. For example, one may advantageously incorporate tissue growth factors such as TGF-beta1, TGF-beta2, PDGF-AA, PDGF-AB, PDGF-BB, EGF, acidic FGF, basic FGF, TGF-alpha, connective tissue activating peptides, beta-thromboglobulin, insulin-like growth factors, tumor necrosis factors, interleukins, colony stimulating factors, erythropoietin, nerve growth factor, interferons, and the like. The presently preferred factors for incorporation are TGF-beta (beta1 and/or beta2) and acidic FGF. The collagen implant in such formulations releases the incorporated additive over an extended period of time into the site of administration.

The ability of the collagen implants to deliver active substances over a period of time is an important aspect of the invention. The wound healing matrices containing active substances generate a more optimal wound healing response than active substances alone. This response includes persistence of granulation tissue deposition, reepithelialization and vascularization of the wound, and ultimately complete healing of the wound. The matrices of the invention provide several advantages over frequent administration (such as by repeated injection) of active substances alone. These advantages include (1) the ability to maintain the active substance at the treated site over a period of time following each administration, (2) optimal handling properties for the physician, (3) decreased trauma to the patient (e.g., 1-3 treatments per week instead of treatments daily or more), and (4) decreased treatment costs to the patient. Furthermore, the collagen composition of these matrices provides an environment similar to host tissue, encouraging the wound healing response, and is replaced by host tissue as the matrix degrades over time.



### C. Examples

The invention is further illustrated by the following Examples. These are provided merely to set forth in more detail the practice of the invention, and are not to be construed as a limitation on the scope of the invention.

#### Example 1

##### (Preparation of Collagen Implants)

10

A collagen implant suitable for use as a wound healing matrix is prepared as follows:

Nine (9) parts of flowable viscous Vitrogen® 100 collagen in aqueous solution, having a concentration of about 3 mg/mL, is precipitated by adding 1.0 part by volume of 0.2 M  $\text{Na}_2\text{HPO}_4$ /0.09 M NaOH, pH 11.2 buffer. The amount of base in the buffer is selected to neutralize the acid in the Vitrogen® 100 solution. The precipitation is carried out at ambient temperature. The precipitate that forms is collected by centrifugation and then homogenized to give a homogenous dispersion. The concentration of protein in the homogenate is then determined and found to be 40-70 mg/mL. A portion of the homogenate is diluted to a collagen concentration of 5 mg/mL with 0.02 M  $\text{Na}_2\text{HPO}_4$ /0.13 M NaCl, pH 7.4.

The homogenate is spread on a metal sheet to a thickness of about 5 mm. The metal sheet is then placed in a  $-80^\circ\text{C}$  cooler for one hour. This time period is probably longer than needed since the layer is observed to freeze very rapidly under these conditions.

The solid layer so formed is placed in a lyophilizer and allowed to warm to about  $-20^\circ\text{C}$  while drawing a vacuum of about 0.0133 mbar (0.01 mm Hg). This is continued for 24 hours, until less than about 25 wt % moisture is present.

The lyophilized layer is then allowed to warm to  $15-20^\circ\text{C}$  and dried under vacuum for about 8 hours to remove residual free moisture. The implant has a fine homogenous fibrillar structure and is very dense, coherent, and resistant to tearing. This implant is useful as a wound healing implant or as a burn dressing or the like.

#### 30 Example 2

##### (Preparation of Implant With Air)

Example 1 is repeated with one change. A volume of the homogenate is placed in a chamber and coupled to a second chamber containing one tenth of its volume of air. The air is injected into the homogenate and the two phases are gently pumped from chamber to chamber until the entire volume of air has been incorporated to give a gas in semisolid dispersion. The dispersion is further processed as in Example 1 to give a solid implant of fibrillar collagen. The implant is less dense than the matrix produced in Example 1, and is easy to tear apart. Although not measured quantitatively, qualitatively it is less strong than the implant of Example 1, that is it is less resistant to tearing. It is also not as stiff as the implant of Example 1. This implant is also useful as a wound healing matrix.

#### Example 3

##### 45 (Preparation of Compressed Implants)

The resultant implants made by either of Examples 1 or 2 are further processed by passing individual implant(s) through a roller press to compress each layer into a uniform thickness of about 1 mm. Compressed implants are more dense and more resistant to tearing. Compressed implants would be used as long-term protective coverings for a wound, while also providing a wound-healing environment.

#### Example 4

##### (Preparation of Collagen/Heparin Implants)

55

Medical grade heparin is dissolved in 0.02 M  $\text{Na}_2\text{HPO}_4$  buffer, pH 7.8 to a concentration of 500-1500  $\mu\text{g/mL}$ . The heparin solution is added to a collagen dispersion prepared as in Example 1 but containing 7.5 mg/mL fibrillar collagen to provide dispersions containing 100  $\mu\text{g/mL}$  heparin and 5  $\mu\text{g/mL}$  heparin. The

dispersions are then flash-frozen and lyophilized as in Example 1. The resulting collagen-heparin implants are then placed in a vacuum oven and heat-cured at room temperature or 80 °C for 24 h. Tests were carried out in triplicate.

Mechanical strength of the cured implants was measured using a tension test which determines the rupture strength of wet sponges by pulling with a hanging weight. Dry samples of the implants were cut in 2 x 1 cm<sup>2</sup> pieces and glued to plastic anchor plates using Permabond® 910 adhesive. The implants were then wetted with phosphate buffered saline for 5 min before clamping down one end of the plastic plate to a stationary board. The clamped sample was stressed with a 20 g hanging weight. The time to break the implant was measured in seconds. This time is referred to as "strength time". Test results are shown in Table 1 below.

TABLE 1

|                                       |                                  |                              |            |                |                     |      |
|---------------------------------------|----------------------------------|------------------------------|------------|----------------|---------------------|------|
| 15                                    | Sample Composition Before Drying |                              | Treatment  | Thickness (mm) | Strength Time (Sec) | Ave. |
|                                       | A.                               | 7.5 mg/mL FC<br>100 μg/mL HP | Room Temp. | 2              | 10.0                | 11   |
|                                       |                                  |                              | Vac        | 2              | 3.1                 |      |
| 24 h                                  |                                  |                              | 2          | 18.9           |                     |      |
| 20                                    | B.                               | 7.5 mg/mL FC<br>100 μg/mL HP | 80 °C      | 2              | 397                 | 415  |
|                                       |                                  |                              | Vac        | 2              | 77                  |      |
|                                       |                                  |                              | 24 h       | 2              | 771                 |      |
| 25                                    | C.                               | 7.5 mg/mL FC<br>5 μg/mL HP   | Room Temp. | 2              | <1                  | <1   |
|                                       |                                  |                              | Vac        | 2              | <1                  |      |
|                                       |                                  |                              | 24 h       | 2              | <1                  |      |
| 30                                    | D.                               | 7.5 mg/mL FC<br>5 μg/mL HP   | 80 °C      | 2              | 21.5                | 69   |
|                                       |                                  |                              | Vac        | 2              | 170.4               |      |
|                                       |                                  |                              | 24 h       | 2              | 14.1                |      |
| HP: heparin<br>FC: fibrillar collagen |                                  |                              |            |                |                     |      |

The results of Table 1 show that the tear strength of the implants can be increased by heat curing.

Pore sizes of the cured collagen-heparin implants were measured using light microscopy. The pore size results are shown in Table 2 below.

TABLE 2

| Sample Composition Before Drying                  |                              | Treatment                 | Ave. Pore Size | Pore Size Range |
|---|------------------------------|---------------------------|----------------|-----------------|
| A.  | 7.5 mg/mL FC<br>100 µg/mL HP | Room Temp.<br>Vac<br>24 h | 103±63         | 45-282          |
| B.  | 7.5 mg/mL FC<br>100 µg/mL HP | 80 °C<br>Vac<br>24 h      | 93±31          | 48-162          |
| C.  | 7.5 mg/mL FC<br>5 µg/mL HP   | Room Temp.<br>Vac<br>24 h | 57±19          | 27-109          |
| D.  | 7.5 mg/mL FC<br>5 µg/mL HP   | 80 °C<br>Vac<br>24 h      | 74±28          | 32-98           |
| Pore size in micrometers: all implants 2 mm thick |                              |                           |                |                 |

As shown in Table 2, the amount of heparin added to the implant affects the pore size of the implant.

#### Example 5

##### 5 (Preparation of Collagen/Factor Implant)

A collagen/heparin implant containing transforming growth factor-beta (TGF-beta) was prepared as follows:

##### 10 (A) Preparation of TGF-beta

TGF-beta was prepared as described in US Patent No. 4,774,322. The procedure is as follows:

Bovine metatarsal bone was obtained fresh from a slaughterhouse and transported on dry ice. The bones were cleaned of marrow and non-bone tissues, broken into fragments <1 cm in diameter, and pulverized in a mill at 4 °C. The pulverized bone was washed twice with 9.4 L of double distilled water per Kg of bone for about 15 min each, then washed overnight in 0.01 N HCl at 4 °C. Washed bone was defatted using 3 x 3 volumes ethanol, followed by 3 x 3 volumes diethyl ether (20 min each at room temperature). The resulting defatted bone powder was then demineralized in 0.5 N HCl (25 L/Kg defatted bone) at 4 °C. The acid was decanted, and the resulting demineralized bone (DMB) washed with water until the wash pH was greater than 4, followed by drying on a suction filter.

The DMB was then extracted with 3.3 L of 4 M guanidine-HCl, 10 mM EDTA, pH 6.8, 1 mM PMSF, 10 mM NEM per Kg for 16 hours, the suspension suction filtered, and the insoluble material extracted again for 4 h. The soluble fractions were combined and concentrated at least 5-fold by ultrafiltration using an Amicon ultrafiltration (10K) unit, and the concentrate dialyzed against 6 changes of 35 volumes cold deionized water over a period of 4 days, and then lyophilized. (All procedures performed at 4 °C, except for lyophilization.)

The resulting protein extract was redissolved in 4 M guanidine-HCl, fractionated on a Sephacryl® S-200 column equilibrated in 4 M guanidine-HCl, 0.02% Na<sub>3</sub>, 10 mM EDTA, pH 6.8. Fractions were assayed by their absorbances at 280 nm and their chondrogenic activity (using ELISA to measure the appearance of characteristic proteoglycans in chondrocyte cell culture), and the fractions combined. The fraction exhibiting greatest activity (protein mw 10,000-40,000 daltons) was dialyzed against 6 changes of 180 volumes of deionized water and lyophilized.

The fraction was then dissolved in 6 M urea, 10 mM NaCl, 1 mM NEM, 50 mM sodium acetate (NaOAc), pH 4.8, and centrifuged at 10,000 rpm for 5 min. The supernatant was fractionated on a CM52 column (2.5 x 20 cm) equilibrated in the same buffer. Bound proteins were eluted from the column using a 10 mM to 400 mM NaCl gradient in the same buffer, and a total volume of 350 mL at a flow rate of 27 mL/h. The eluate was pooled into three fractions (A, B, and C). Fractions B and C eluted at approximately 150-250 mM NaCl. Each fraction was dialyzed against 6 changes of 110 volumes of deionized water for 4 days, and then lyophilized.

The lyophilized fractions A and BC (combined) were dissolved in 0.1% trifluoroacetic acid (TFA), and aliquots of the solutions applied to a Vydac® C18 RP-HPLC column (4.6 mm ID x 25 cm) and washed with 0.1% TFA for 5 min at 1 mL/min. The eluting solvent was a 0-60% CH<sub>3</sub>CN gradient in 0.1% TFA at a rate of 2%/min. Fraction BC provided two peaks: peak 1 at 29.5 min containing TGF-beta1, and peak 2 at 31.2 min containing TGF-beta2.

##### 45 (B) Preparation of collagen/TGF-beta implant:

TGF-beta1 was dissolved in acidic solution (pH 2.0), diluted, and reconstituted with collagen in solution (CIS) to provide a final concentration of 30 µg/mL TGF-beta1 and 300 µg/mL CIS. The solution was then filtered through a 0.22 µm Millex®-GV filter unit to sterilize the protein factor. The sterile TGF-beta1/CIS solution was then mixed with 0.2 M Na<sub>2</sub>HPO<sub>4</sub> buffer (pH 11.2) to make a storable dispersion containing 27 µg/mL TGF-beta1 and 270 µg/mL CIS.

Medical grade heparin was dissolved in 0.02 M Na<sub>2</sub>HPO<sub>4</sub> buffer (pH 7.8) to provide a 400 µg/mL heparin solution. One part heparin solution was added to an equal volume of collagen solution (prepared as in Example 1, but containing 30 mg/mL) to provide a collagen/heparin slurry containing 200 µg/mL heparin and 15 mg/mL collagen. One part of this dispersion was mixed with 1 part of the collagen/TGF-beta1 dispersion to provide a final dispersion having 7.6 mg/mL collagen, 100 µg/mL heparin, and 13.5 µg/mL TGF-beta1.

The resulting dispersion was then poured into molds, placed in a Virtis® SRC15 freeze dryer, and equilibrated to 4 °C. The dispersion was then flash-frozen and lyophilized as provided in Example 1.

(C) Similarly, proceeding as in part B above but substituting TGF-beta2 for TGF-beta1, a TGF-beta2/collagen implant of the invention was prepared.

5 (D) Similarly, proceeding as in part B above but substituting PDGF for TGF-beta1, a PDGF/collagen implant of the invention was prepared.

#### Example 6

##### 10 (Wound Healing in Animal Models)

Healing of full thickness wounds in guinea pigs was studied in the following experiment.

The following implant formulations were first prepared:

1. 7.5 mg/mL collagen, 100 µg/mL heparin, 4.0 µg/mL TGF-beta1
- 15 2. 7.5 mg/mL collagen, 100 µg/mL heparin, 20 µg/mL TGF-beta1
3. none (control)

The dispersions (1.2 mL) were cast and lyophilized as described above to provide strips 4.5 cm x 1.3 cm x 0.15 cm.

A midline incision 5 cm long through the cutaneous muscle was made in the dorsal skin of 60 male  
20 Hartley guinea pigs. The skin edges were allowed to gape open to form longitudinal lenticular-shaped wounds 5 cm by about 1.2 cm at midpoint, with a mean surface area of 4.2 cm<sup>2</sup>. Twelve animals were used for each test group. A strip of the test formulation (or control) was inserted in the wound, allowed to hydrate, and molded as necessary to cover the entire base of the defect. The wounds were then covered with Opsite®, and dressed.

25 Four animals from each group were studied on days 14 and 21. The wound sites were explanted and examined histologically for epithelialization and deposition of connective and granulation tissue.

The results indicated that at 14 days, wounds receiving implants containing TGF-beta1 were stronger than wounds receiving matrix only. At 21 days, wounds receiving 4 µg TGF-beta1 were significantly stronger than wounds receiving 20 µg TGF-beta1. The results suggest that treatment with TGF-beta1  
30 collagen/heparin matrix can enhance the strength of open wounds at earlier stages of healing.

#### Example 7

##### (Persistence of Fibrotic Response)

35 The beneficial long-term persistence of the fibrotic response (e.g., connective tissue deposition, fibroplasia, and angiogenesis) induced by the wound healing matrix containing a bioactive agent was studied in the following experiment. The test compositions were prepared as follows:

- A: TGF-beta1 (1.5 µg) in PBS (daily injections);
- 40 B: TGF-beta1 (10.5 µg) in PBS (bolus);
- C: Fibrillar collagen (32 mg/mL) + heparin (300 µg/mL) ("FCH gel");
- D: Fibrillar collagen (32 mg/mL) + heparin (300 µg/mL) + TGF-beta1 (10.5 µg);
- E: Fibrillar collagen (7.5 mg/mL) + heparin (100 µg/mL) ("matrix");
- F: Fibrillar collagen (7.5 mg/mL) + heparin (100 µg/mL) + TGF-beta1 (10.5 µg).

45 Each formulation additionally contained 500 µg/mL mouse serum albumin (MSA). To prepare the dried collagen matrices, the dispersions of samples E and F were cast and frozen at -40 °C for 2 hours in a lyophilizer. Then, the lyophilization chamber was evacuated and the temperature increased to -20 °C for 24 hours. This lyophilization process was completed by raising the temperature to 20 °C for an additional 24 hours.

50 Twelve adult female Swiss Webster mice were used in each test group. Group A received sample A by daily injection into the nuchal subcutaneum for 7 days. Groups B, C, and D were injected only on day 1 with the respective test formulations into the nuchal subcutaneum. Groups E and F received their respective test formulations by surgical subcutaneous implantation in the scapular region (the wounds were closed with clips). Explants were taken from each group on days 7, 15 and 30 for histological and morphometric  
55 analysis.

Four animals per group were studied at each time point. After 7 days, connective tissue deposition and neovascularization at the administration site were observed in groups that received TGF-beta1. There was a significantly more extensive response in group A (TGF-beta daily), group D (FCH gel + TGF-beta1), and

group F (matrix + TGF-beta1), compared to the other groups. After 15 days, administration sites in group F had a significantly greater response than sites in groups B, C, or E. At both day 7 and 15, there were no significant differences between the sites in group A, D, or F. By day 30, there were no significant differences between groups A and D. However, the extent of the response to TGF-beta1 declined steadily in groups A and D, but much more slowly in group F. The data indicates that the persistence of the fibrotic response at subcutaneous sites in adult mice increases when sites are treated with growth factors presented in the collagen matrices of the invention, rather than with growth factors alone.

#### Example 8

10

(Wound Healing Without Factors)

The ability of the wound healing matrix without added biological growth factors to enhance healing in dermal wounds was demonstrated in the following experiment. Wound healing normally consists of deposition of granulation tissue (vascular and connective tissue) in the wound defect.

Collagen matrix was formulated containing 7.5 mg/mL of fibrillar collagen, 100 µg/mL heparin, and 0.5 mg/mL of porcine serum albumin.

Lenticular dermal wounds 5 cm in length were created in the skin of domestic pigs. A strip of collagen/heparin matrix (4.5 x 0.4 x 0.15 cm) was placed into each of 15 full thickness dermal wounds and hydrated with a few drops of saline. Fifteen similar wounds were left untreated. All wounds were covered with transparent occlusive dressing and gauze sponge, secured with circumferential wrappings of elastic tape. At days 3, 7, and 14, 5 wounds from each treatment group were excised from the animal and examined with histomorphometrical techniques.

At all times, the mean amount of granulation tissue in the wounds treated with matrix was significantly greater than in untreated wounds ( $F(2,30) = 19.4$ ,  $p = 0.0001$ ). In particular, at day 7, granulation tissue was greater in the matrix treated wounds ( $F(1,30) = 32.0$ ,  $p < 0.005$ ).

The data demonstrates that the collagen matrix enhances wound healing even in the absence of additional factors, by stimulating the deposition of increased amounts of granulation tissue in the wound.

#### Example 9

30

(Combined aFGF and TGF-B)

Wound healing formulations prepared with approximately equal amounts of acidic fibroblast growth factor (aFGF) and TGF-B exhibit synergistic enhancement of wound healing activity.

Nine (9) parts of flowable, viscous Vitrogen® 100 collagen in aqueous solution, having a concentration of about 3 mg/mL, was precipitated by adding 1.0 part by volume of 0.2 M  $\text{Na}_2\text{HPO}_4$ /0.09 M NaOH, pH 11.2 buffer. The amount of base in the buffer was selected to neutralize the acid in the Vitrogen® 100 solution. The precipitation was carried out at 20 °C for about 6 hours. The precipitate that formed was collected by centrifugation and then homogenized to give a homogenous dispersion. The concentration of protein in the homogenate was determined to be about 56 mg/mL. This homogenate was combined with sodium heparin (8 mg/mL), aFGF (470 µg/mL), and TGF-B2 (522 µg/mL) as described in the examples above to provide collagen/heparin sponge compositions as follows:

45

50

55

| Composition | aFGF ( $\mu\text{g}/\text{cm}^2$ ) | TGF-B2 ( $\mu\text{g}/\text{cm}^2$ ) |
|-------------|------------------------------------|--------------------------------------|
| A           | 17.7                               | 17.7                                 |
| B           | 0.7                                | 17.7                                 |
| C           | 3.5                                | 17.7                                 |
| D           | 17.7                               | 3.5                                  |
| E           | 17.7                               | 0.7                                  |
| F           | 0.7                                | 3.5                                  |
| G           | 3.5                                | 3.5                                  |
| H           | 0.0                                | 17.7                                 |
| I           | 3.5                                | 0.7                                  |
| J           | 0.0                                | 3.5                                  |
| K           | 0.7                                | 0.7                                  |
| L           | 17.7                               | 0.0                                  |
| M           | 0.0                                | 0.7                                  |
| N           | 3.5                                | 0.0                                  |
| O           | 0.7                                | 0.0                                  |
| P           | 0.0                                | 0.0                                  |

These concentrations are calculated to provide 5, 1, or 0.2  $\mu\text{g}$  of factor (or no factor) when the sponge matrix is cut into circles 6 mm in diameter.

Twenty-five adult mice were divided into 5 groups, and full-thickness dermal wounds 6 mm in diameter created in the mid-dorsum of each animal. Immediately after wounding, one of the sponge compositions was placed into the wound, and covered with Opsite® dressing and tape.

At day 7, the wounds were explanted and prepared for histological and histomorphometric examination. The amount of vascular and non-vascular connective tissue in histological cross-sections of the wounds was measured planimetrically using a camera lucida and digitizer tablet. The results are graphically depicted in Figure 3. The stippled bars indicate the observed connective tissue deposited in response to the matrix, while the open bars indicate the "expected" amount of connective tissue assuming only additive effects. The bars are arranged in the same order as the formulations above (e.g., "A", 17.7  $\mu\text{g}/\text{cm}^2$  aFGF + 17.7  $\mu\text{g}/\text{cm}^2$  TGF-B2, corresponds to the 5  $\mu\text{g}$  aFGF + 5  $\mu\text{g}$  TGF-B2 bar). Administration of aFGF in combination with TGF-B2 synergistically increased granulation tissue significant over administration of either factor alone. This demonstrates that the combination of aFGF and TGF-B is synergistically effective in promotion of healing in dermal wounds.

Modifications of the above described modes for carrying out the invention that are obvious to those of skill in the art of collagen chemistry and/or wound dressings are intended to be within the scope of the following claims.

#### Claims

1. A collagen implant, comprising:  
a matrix having a density of about 0.01 to about 0.3  $\text{g}/\text{cm}^3$ , a thickness of about 1-20 mm, and having pores at least 80% of which are at least 35  $\mu\text{m}$  in diameter, wherein said matrix comprises fibrillar atelopeptide collagen, wherein said fibrils are about 50-200 nm in diameter, and are not chemically cross-linked.
2. The implant of claim 1 which further comprises heparin.
3. The implant of claim 2 wherein the heparin is at a concentration of between 5  $\mu\text{g}/\text{ml}$  and 500  $\mu\text{g}/\text{ml}$ .
4. The implant of any one of claims 1 to 3 which further comprises an amount of a biological growth factor effective for wound healing, oncogenesis, immunomodulation, osteogenesis, or hematopoietic modulation.
5. The implant of claim 4 wherein said growth factor is selected from the group consisting of TGF-beta1, TGF-beta2, PDGF-AA, PDGF-AB, PDGF-BB, EGF, acidic FGF, basic FGF, TGF-alpha, connective tissue activating peptides, beta-thromoglobulin, insulin-like growth factors, tumor necrosis factors, interleukins, colony stimulating factors, erythropoietin, nerve growth factor, and interferons.

6. The implant of claim 5 which comprises a synergistic wound-healing effective amount of TGF-B and FGF.
7. The implant of claim 6 wherein said effective amount of TGF-B and FGF is from 0.07 to 200  $\mu\text{g}/\text{cm}^2$  of composition.
8. The implant of claim 6 or 7 wherein said TGF-B is native bovine TGF-B, and said FGF is recombinant human acidic FGF.
9. A process for preparing the collagen implant of any one of claims 1 to 8 which includes the steps of:
  - (a) providing an acidic aqueous solution of atelopeptide collagen at a concentration of collagen of from 2 to less than 20 mg/ml;
  - (b) precipitating the collagen from the solution by raising the pH of the solution, forming a homogenous dispersion of the precipitated collagen fibrils;
  - (c) casting the dispersion to a desired thickness;
  - (d) flash-freezing the cast dispersion at a temperature below about  $-20^\circ\text{C}$ ; and
  - (e) lyophilizing the frozen cast dispersion to form a substantially moisture-free collagen matrix.
10. The process of claim 9 wherein said acidic aqueous solution comprises about 4 to less than 20 mg/ml atelopeptide collagen.
11. The process of claim 9 or 10 wherein the implant has a water content of 1-25%.
12. The process of any one of claims 1 to 3 further characterized by:  
mixing 0.33 to 3.0 volumes to inert gas into said dispersion prior to casting.
13. The process of any one of claims 9 to 12 wherein said process is further characterized by:  
heating said collagen matrix at about  $60^\circ\text{C}$  to about  $120^\circ\text{C}$  for between about 4 hours and one week, at a relative humidity of less than about 55%.
14. The process of claim 13 wherein said heating is performed at about  $75-90^\circ\text{C}$ .
15. The process of any one of claims 9 to 14 further characterized by:  
compressing said collagen matrix to a density of about  $0.05-0.3\text{ g}/\text{cm}^3$ .
16. An implant according to any one of claims 1 to 8 for use in a method of treatment of the human or animal body.
17. An implant for use according to claim 16 wherein the method of treatment comprises healing a wound, inhibiting tumor growth, effecting immunomodulation or effecting hematopoiesis.

#### Patentansprüche

1. Kollagenimplantat, das umfaßt:  
eine Matrix mit einer Dichte von etwa 0,01 bis etwa  $0,3\text{ g}/\text{cm}^3$ , einer Dicke von etwa 1-20 mm und Poren, von denen mindestens 80 % einen Durchmesser von 35  $\mu\text{m}$  aufweisen, wobei diese Matrix umfaßt  
fibrilläres Atelopeptidkollagen worin diese Fibrillen einen Durchmesser von etwa 50-200 nm aufweisen und nicht chemisch quervernetzt sind.
2. Implantat nach Anspruch 1, das ferner Heparin umfaßt.
3. Implantat nach Anspruch 2, worin das Heparin eine Konzentration zwischen 5  $\mu\text{g}/\text{ml}$  und 500  $\mu\text{g}/\text{ml}$  aufweist.
4. Implantat nach einem der Ansprüche 1 bis 3, das ferner eine Menge eines biologischen Wachstumsfaktors umfaßt, der bei der Wundheilung, Onkostase, Immunmodulation, Osteogenese oder hämatopoetischen Modulation wirksam ist.

5. Implantat nach Anspruch 4, worin dieser Wachstumsfaktor aus der Gruppe ausgewählt ist, die besteht aus TGF-beta 1, TGF-beta 2, PDGF-AA, PDGF-AB, PDGF-BB, EGF, saurem FGF, basischem FGF, TGF-alpha, Bindegewebeaktivierungspeptiden, beta-Thromboglobulin, Insulin-ähnlichen Wachstumsfaktoren, Tumornekrosefaktoren, Interleukinen, Kolonie-stimulierenden Faktoren, Erythropoetin, Nervenwachstumsfaktor und Interferonen.
6. Implantat nach Anspruch 5, das eine bei der Wundheilung synergistisch wirksame Menge von TGF-B und FGF umfaßt.
7. Implantat nach Anspruch 6, worin diese wirksame Menge von TGF-B und FGF 0,07 bis 200 µg/cm<sup>2</sup> der Zusammensetzung beträgt.
8. Implantat nach Anspruch 6 oder 7, worin dieses TGF-B natives TGF-B aus dem Rind ist und dieses FGF rekombinantes humanes saures FGF ist.
9. Verfahren zur Herstellung des Kollagenimplantats nach einem der Ansprüche 1 bis 8, das folgende Schritte beinhaltet:
  - (a) Bereitstellung einer sauren wäßrigen Lösung des Atelopeptidkollagens mit einer Konzentration an Kollagen von 2 bis weniger als 20 mg/ml,
  - (b) Ausfällung des Kollagens aus der Lösung durch Erhöhung des pH der Lösung, Bildung einer homogenen Dispersion der gefällten Kollagenfibrillen,
  - (c) Gießen der Dispersion in eine gewünschte Dicke,
  - (d) Schockgefrieren der gegossenen Dispersion bei einer Temperatur unter etwa -20 °C, und
  - (e) Lyophilisierung der gefrorenen gegossenen Dispersion unter Bildung einer im wesentlichen feuchtigkeitsfreien Kollagenmatrix.
10. Verfahren nach Anspruch 9, worin diese saure wäßrige Lösung etwa 4 bis weniger als 20 mg/ml Atelopeptidkollagen umfaßt.
11. Verfahren nach Anspruch 9 oder 10, worin das Implantat einen Wassergehalt von 1-25 % aufweist.
12. Verfahren nach einem der Ansprüche 1 bis 3 ferner gekennzeichnet durch: Mischen von 0,33 bis 3,0 Volumina eines inerten Gases in diese Dispersion vor dem Gießen.
13. Verfahren nach einem der Ansprüche 9 bis 12, worin dieses Verfahren ferner gekennzeichnet ist durch: Aufheizen der Kollagenmatrix auf etwa 60 °C bis etwa 120 °C zwischen etwa 4 Stunden und einer Woche bei einer relativen Luftfeuchtigkeit von weniger als etwa 55 %.
14. Verfahren nach Anspruch 13, worin das Aufheizen bei etwa 75-90 °C durchgeführt wird.
15. Verfahren nach einem der Ansprüche 9 bis 14 ferner gekennzeichnet durch: Pressen dieser Kollagenmatrix auf eine Dichte von etwa 0,05-0,3 g/cm<sup>3</sup>.
16. Implantat nach einem der Ansprüche 1 bis 8 zur Verwendung in einem Behandlungsverfahren des menschlichen oder tierischen Körpers.
17. Implantat zur Verwendung nach Anspruch 16, worin das Behandlungsverfahren die Heilung einer Wunde, die Hemmung eines Tumorstwachstums, die Bewirkung einer Immunmodulation oder die Bewirkung der Hämatopoese umfaßt.

#### Revendications

1. Implant de collagène, comprenant:  
une matrice ayant une densité d'environ 0,01 à environ 0,3 g/cm<sup>3</sup>, une épaisseur d'environ 1 à 20 mm et ayant des pores dont au moins 80% ont un diamètre d'au moins 35 µm, dans lequel cette matrice comprend:  
du collagène atelopeptide fibrillaire, dans lequel ces fibrilles ont un diamètre d'environ 50 à 200 nm, et ne sont pas réticulées chimiquement.



2. Implant suivant la revendication 1, qui comprend de plus de l'héparine.
3. Implant suivant la revendication 2, dans lequel l'héparine est à une concentration comprise entre 5  $\mu\text{g/ml}$  et 500  $\mu\text{g/ml}$ .
- 5 4. Implant suivant l'une quelconque des revendications 1 à 3, qui comprend de plus une quantité d'un facteur de croissance biologique efficace pour réaliser la cicatrisation des plaies, l'oncostase, l'immuno-modulation, l'ostéogénèse ou la modulation hématopoïétique.
- 10 5. Implant suivant la revendication 4, dans lequel ce facteur de croissance est choisi dans le groupe consistant en TGF-béta-1, TGF-béta-2, PDGF-AA, PDGF-AB, PDGF-BB, EGF, FGF acide, FGF basique, TGF-alpha, peptides activant le tissu conjonctif, béta-thromboglobuline, facteurs de croissance analogue à l'insuline, facteurs de nécrose tumorale, interleukines, facteurs stimulant des colonies, érythro-poïétine, facteur de croissance des cellules nerveuses et interférons.
- 15 6. Implant suivant la revendication 5, qui comprend une quantité synergique efficace pour cicatriser les plaies de TGF-B et de FGF.
- 20 7. Implant suivant la revendication 6, dans lequel cette quantité efficace de TGF-B et de FGF est comprise entre 0,07 et 200  $\mu\text{g/cm}^2$  de composition.
8. Implant suivant les revendications 6 ou 7, dans lequel ce TGF-B est un TGF-B bovin naturel, et ce FGF est un FGF acide humain recombinant.
- 25 9. Procédé pour la préparation de l'implant de collagène suivant l'une quelconque des revendications 1 à 8, qui comprend les étapes de :
  - (a) fourniture d'une solution aqueuse acide de collagène atélopeptide ayant une concentration de collagène comprise entre 2 et moins de 20 mg/ml;
  - (b) précipitation du collagène à partir de la solution par élévation du pH de la solution, formant une
  - 30 dispersion homogène de fibrilles de collagène précipitées;
  - (c) coulée de la dispersion en une épaisseur désirée;
  - (d) congélation éclair de la dispersion coulée à une température inférieure à environ  $-20^\circ\text{C}$ ; et
  - (e) lyophilisation de la dispersion coulée congelée pour former une matrice de collagène pratiquement exempte d'humidité.
- 35 10. Procédé suivant la revendication 9, dans lequel cette solution aqueuse acide comprend environ 4 à moins de 20 mg/ml de collagène atélopeptide.
- 40 11. Procédé suivant les revendications 9 ou 10, dans lequel l'implant a une teneur en eau de 1 à 25%.
12. Procédé suivant l'une quelconque des revendications 9 à 11, caractérisé de plus par le mélange de 0,33 à 3,0 volumes de gaz inerte dans cette dispersion avant la coulée.
- 45 13. Procédé suivant l'une quelconque des revendications 9 à 12, caractérisé de plus par le chauffage de cette matrice de collagène à une température comprise entre environ  $60^\circ\text{C}$  et environ  $120^\circ\text{C}$  pendant une période comprise entre environ 4 heures à une semaine, à une humidité relative inférieure à environ 55%.
- 50 14. Procédé suivant la revendication 13, dans lequel ce chauffage est réalisé à une température comprise entre environ  $75^\circ\text{C}$  et  $90^\circ\text{C}$ .
15. Procédé suivant l'une quelconque des revendications 9 à 14, caractérisé de plus par la compression de cette matrice de collagène à une densité comprise entre environ 0,05 et 0,3  $\text{g/cm}^3$ .
- 55 16. Implant suivant l'une quelconque des revendications 1 à 8, utilisable dans une méthode de traitement du corps humain ou animal.

- 17.** Implant utilisable suivant la revendication 16, dans lequel la méthode de traitement comprend la cicatrisation d'une plaie, l'inhibition d'une croissance tumorale, la réalisation d'une immunomodulation ou la réalisation d'une hématopoïèse.

5

10

15

20

25

30

35

40

45

50

55




FIG. 1




FIG. 2

**FIG. 3** **TOTAL CONNECTIVE TISSUE**

